Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT-Reference-Cited by-同舟云学术

Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT

Published:2019-06-14 Issue: Volume:10 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Risitano Antonio M.,Marotta Serena,Ricci Patrizia,Marano Luana,Frieri Camilla,Cacace Fabiana,Sica Michela,Kulasekararaj Austin,Calado Rodrigo T.,Scheinberg Phillip,Notaro Rosario,Peffault de Latour Regis

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference172 articles.

1. Paroxysmal Nocturnal Hemoglobinuria;Risitano,2012

2. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria;Takeda;Cell.,1993

3. Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene;Bessler;EMBO J.,1994

4. Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria;Miyata;N Engl J Med.,1994

5. Defective glycosylphosphatidylinositol anchor synthesis in paroxysmal nocturnal hemoglobinuria granulocytes;Mahoney;Blood.,1992

Cited by 152 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Navigating the Complement Pathway to Optimize PNH Treatment with Pegcetacoplan and Other Currently Approved Complement Inhibitors;International Journal of Molecular Sciences;2024-08-31

2. Three Years On: The Role of Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH) since Its Initial Approval;International Journal of Molecular Sciences;2024-08-09

3. Moving toward Individual Treatment Goals with Pegcetacoplan in Patients with PNH and Impaired Bone Marrow Function;International Journal of Molecular Sciences;2024-08-06

4. The complement model disease paroxysmal nocturnal hemoglobinuria;European Journal of Immunology;2024-08-05

5. Improvements in hematologic markers and decreases in fatigue with pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and mild or moderate anemia (hemoglobin ≥10 g/dL) who had received eculizumab or were naive to complement inhibitors;PLOS ONE;2024-07-29